ZNF92 and prostate carcinoma: The TF12-based pre-targeted radio-immunoimaging strategy, when combined with 68Ga di-HSG peptide IMP288 (68Ga-IMP288), achieved rapid, highly sensitive, and specific imaging in prostate cancer models 91.